Obesity Clinical Trials in Austin, Texas

19 studies are recruiting for obesity in Austin, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

   This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Austin Heart, Austin, Texas

   Locations

   657 in total

   Run by

   Amgen

   See if you can join NCT07037459 on ClinicalTrials.gov

2. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

   Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-2 Clinical Site, Austin, Texas

   Locations

   135 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743450 on ClinicalTrials.gov

3. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

   Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-1 Clinical Site, Austin, Texas

   Locations

   122 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743463 on ClinicalTrials.gov

4. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

   This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-2 Research Site, Austin, Texas

   Locations

   74 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654374 on ClinicalTrials.gov

5. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

   The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   IMA Clinical Research Austin, Austin, Texas

   Locations

   56 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06143956 on ClinicalTrials.gov

6. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   IMA Clinical Research Austin, Austin, Texas

   Locations

   157 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07282600 on ClinicalTrials.gov

7. A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

   The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   FutureSearch Trials of Neurology, Austin, Texas

   Locations

   115 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07369011 on ClinicalTrials.gov

8. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

   The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

   Stage

   Phase 3

   Ages

   45 to 99

   Site

   Austin Heart, Austin, Texas

   Locations

   783 in total

   Run by

   Amgen

   See if you can join NCT07037433 on ClinicalTrials.gov

9. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

   The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Elligo Clinical Research Center, Austin, Texas

   Locations

   37 in total

   Run by

   Amgen

   See if you can join NCT07684144 on ClinicalTrials.gov

10. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    Elligo Clinical Research Center, Austin, Texas

    Locations

    87 in total

    Run by

    Amgen

    See if you can join NCT07684235 on ClinicalTrials.gov

11. A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

    This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Texas Diab & Endo, P.A., Austin, Texas

    Locations

    303 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07564414 on ClinicalTrials.gov

12. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

    Stage

    Phase 3

    Ages

    6 to 17

    Site

    Dell Children's Medical Center - PIN, Austin, Texas

    Locations

    117 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06672549 on ClinicalTrials.gov

13. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Austin Heart, Austin, Texas

    Locations

    838 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

14. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

    Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

    Stage

    Phase 3

    Ages

    18 to 79

    Site

    ACCOMPLISH-1 Research Site, Austin, Texas

    Locations

    71 in total

    Run by

    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654361 on ClinicalTrials.gov

15. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    IMA Clinical Research Austin, Austin, Texas

    Locations

    40 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07589608 on ClinicalTrials.gov

16. Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

    This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    FutureSearch Trials of Neurology, Austin, Texas

    Locations

    61 in total

    Run by

    Amgen

    See if you can join NCT07225686 on ClinicalTrials.gov

17. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

    The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Elligo Clin Res Centre, Austin, Texas

    Locations

    11 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07607587 on ClinicalTrials.gov

18. Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)

    Middle-aged women with (overweight/)obesity who will begin or have begun GLP-1 medication use will be recruited to complete a 12-week diet intervention study. For 12-weeks, participants will continue to take their GLP-1 medication and may be provided with protein-rich foods to consume every day. Bo…

    Stage

    Not phased

    Ages

    30 to 60

    Site

    Dell Pediatric Research Center, Austin, Texas

    Locations

    2 in total

    Run by

    University of Texas at Austin

    See if you can join NCT07480109 on ClinicalTrials.gov

19. Semaglutide for Post-Smoking Cessation Weight Management

    This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    The University of Texas at Austin, Austin, Texas

    Locations

    2 in total

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT06173778 on ClinicalTrials.gov